DASH Eating Plan
Also known as: DASH Diet, Dietary Approaches to Stop Hypertension
Methodology & AI Transparency ⓘ
DASH Eating Plan Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: DASH stands for Dietary Approaches to Stop Hypertension.
- 2 Real-world patient consensus: Mapped to High Blood Pressure & Vascular Health under ICD-10-CM I11.1 for DASH Eating Plan clinical workups.
- 3 Typical cash cost range: Workup highlights for DASH Eating Plan (I11.1): vascular stiffness assessment [DASH Eating Plan I11.1].
- 4 Top reported side effects / signs: Follow-up benchmark in DASH Eating Plan: maintaining Serum Creatinine & in DASH Eating Plan (I11.1: Potassium) within K+ 4.0 – 4.8 mEq/L (I11.1).
Ask our AI Specialists anything about DASH Eating Plan
What Is DASH Eating Plan?
DASH stands for Dietary Approaches to Stop Hypertension. It is an eating plan that is based on research studies sponsored by the National Heart, Lung, and Blood Institute (NHLBI). These studies showed that DASH lowers high blood pressure and improves levels of cholesterol . This reduces your risk of getting heart disease . The DASH eating plan: Emphasizes vegetables, fruits, and whole-grains Includes fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils Limits foods that are high in saturated fat. These foods include fatty meats, full-fat dairy products, and tropical oils such as coconut, palm kernel, and palm oils.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying DASH Eating Plan (code I11.1) is Virchow triad prothrombotic in DASH Eating Plan (I11.1: shear stress), Cross-referenced with NIH MeSH (Dietary Approaches To Stop Hypertension), which High Blood Pressure & Vascular Health clinicians address while surveilling Serum Creatinine & in DASH Eating Plan (I11.1: Potassium) (K+ 4.0 – 4.8 mEq/L (I11.1)).
Common Symptoms & Clinical Signs
- • Emphasizes vegetables, fruits, and whole-grains
- • Includes fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils
- • Presentation of DASH Eating Plan (I11.1): localized extremity swelling, in DASH Eating Plan (I11.1: warmth, or venous)
- • Secondary DASH Eating Plan clinical sign: cold distal extremities in DASH Eating Plan (I11.1: or diminished peripheral)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
DASH Eating Plan Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I11.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Creatinine & in DASH Eating Plan (I11.1: Potassium) | K+ 4.0 – 4.8 mEq/L (I11.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [DASH Eating Plan I11.1] | < 15 mg/g (I11.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in DASH Eating Plan (I11.1: Pressure) | < 120/75 mmHg (I11.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for DASH Eating Plan
Treatment selection for DASH Eating Plan depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (DASH Eating Plan)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in high: What a 80,483-Participant Study Found This study suggests that Amlodipine offers greater protection against major complications of high blood pressure compared to intermediate-acting dihydropyridine calcium channel blockers. Journal of cardiovascular pharmacology and therapeutics • 2018-09-15 • Meta-Analysis | N = 80,483 | 94/100 | PMID 29739234 ↗ |
| New Insights on Benefits and safety of moderate-intensity rosuvastatin plus ezetimibe versus: What a 24,592-Participant Study Found Moderate-intensity statin plus ezetimibe with combination therapy had better real-world benefits and safety than high-intensity statins. PloS one • 2024-01-15 • Meta-Analysis | N = 24,592 | 94/100 | PMID 39536001 ↗ |
| Can This Approach Help? Inside the Latest Research on ONTARGET/TRANSCEND Trial Programme: baseline The use of beta-blockers and lipid-lowering therapy, known to reduce mortality and morbidity, is also higher in ONTARGET/TRANSCEND. Acta diabetologica • 2005-04-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 15868120 ↗ |
| Can This Approach Help? Inside the Latest Research on Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Short-term reduction of FFA concentration does not improve insulin-stimulated vasodilation in patients with metabolic syndrome. Endocrinology, diabetes & metabolism • 2025-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39888728 ↗ |
| Can This Approach Help? Inside the Latest Research on Amlodipine reduces blood pressure during dynamic resistance exercise in Amlodipine was effective in reducing the absolute values of systolic and diastolic BP during resistance exercise and in preventing the progressive increase in diastolic BP that occurs over sets of low-intensity exercise. Scandinavian journal of medicine & science in sports • 2015-02-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 24256097 ↗ |
DASH Eating Plan Patient Community & “People Like Me” Threads
Filter DASH Eating Plan community threads and patient logs by age, biological sex, dosage, and treatment duration.